Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy

References

• Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest. 2011;121(3):998–1008.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, lymphoid fibrosis, and disease. Blood. 2012;120(9):1753–1754.
   Web of Science ®Google Scholar
• Hsue PY, Tawakol A. Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter. Circ Cardiovasc Imaging. 2016;9(3):e004427.
   Web of Science ®Google Scholar
• Papagianni M, Tziomalos K. Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection. AIDS Rev. 2018;20(3):171–173.
   Web of Science ®Google Scholar
• Mack M. Inflammation and fibrosis. Matrix Biol. 2018;68–69:106–121.
   PubMed Web of Science ®Google Scholar
• Charo IF, Peters W. Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation. 2003;10(3–4):259–264.
   Web of Science ®Google Scholar
• Ness TL, Kunkel SL, Hogaboam CM. CCR5 antagonists: the answer to inflammatory disease?. Expert Opin Ther Pat. 2006;16(8):1051–1065.
   PubMed Web of Science ®Google Scholar
• Rossi R, Lichtner M, Sauzullo I, et al. Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc. J Acquired Immune Deficiency Syndromes. 2010;54(5):e13–e14.
   Web of Science ®Google Scholar
• Gramegna P, Latronico T, Brana MT, et al. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PloS One.2011;6(12):e28499.
   Web of Science ®Google Scholar
• D’Antoni ML, Mitchell BI, McCurdy S, et al. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018;104(6):1241–1252.
   PubMed Web of Science ®Google Scholar
• D’Antoni ML, Paul RH, Mitchell BI, et al. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism. J Acquir Immune Defic Syndr.2018;79(1):108–116.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–1767.
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PloS One. 2016;11(6):e0158156.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Abdel-Hameed E, Rouster SD, et al. Improvement in hepatic fibrosis biomarkers associated with chemokine receptor inactivation through mutation or therapeutic blockade. Clin Infectious Dis. 2019;68(11):1911–1918.
   Web of Science ®Google Scholar
• Thompson M, Saag M, DeJesus E, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. Aids. 2016;30(6):869–878.
   PubMed Web of Science ®Google Scholar
• Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–1358.
   PubMed Web of Science ®Google Scholar
• Maina EK, Abana CZ, Bukusi EA, Sedegah M, Lartey M, Ampofo WK. Plasma concentrations of transforming growth factor beta 1 in non-progressive HIV-1 infection correlates with markers of disease progression. Cytokine. 2016;81:109–116.
   Web of Science ®Google Scholar
• Theron AJ, Anderson R, Rossouw TM, Steel HC. The role of transforming growth factor beta-1 in the progression of HIV/AIDS and development of non-AIDS-defining fibrotic disorders. Front Immunol. 2017;8:1461.
   Web of Science ®Google Scholar
• Mancini D, Monteagudo J, Suarez-Farinas M, et al. New methodologies to accurately assess circulating active transforming growth factor-beta1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices. Transl Res. 2018;192:15–29.
   Web of Science ®Google Scholar
• Murphy-Ullrich JE, Suto MJ. Thrombospondin-1 regulation of latent TGF-beta activation: A therapeutic target for fibrotic disease. Matrix Biol. 2018;68–69:28–43.
   PubMed Web of Science ®Google Scholar
• Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol. 2008;52(3):211–215.
   PubMed Web of Science ®Google Scholar
• Estes JD. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol Rev. 2013;254(1):65–77.
   PubMedGoogle Scholar
• Schafer S, Viswanathan S, Widjaja AA, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 2017;552(7683):110–115.
   PubMed Web of Science ®Google Scholar
• Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 2011;16(3):405–411.
   Web of Science ®Google Scholar
• Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–395.
   PubMed Web of Science ®Google Scholar
• Coppola N, Perna A, Lucariello A, et al. Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line. J Cell Physiol. 2018;233(8):6224–6231.
   PubMed Web of Science ®Google Scholar
• Wilkening A, Krappe J, Muhe AM, et al. C-C Chemokine Receptor Type 2 Mediates Glomerular Injury and Interstitial Fibrosis in Focal Segmental Glomerulosclerosis. Nephrol Dialysis Transplant. Official Publication of the European Dialysis and Transplant Association - European Renal Association 2018.
   Web of Science ®Google Scholar
• Ng B, Dong J, D’Agostino G, et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med 2019;11(511): eaaw1237.
   PubMed Web of Science ®Google Scholar
• Widjaja AA, Singh BK, Adami E, et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology. 2019;157(3):777–792 e14.
   PubMed Web of Science ®Google Scholar
• Gurfein BT, Zhang Y, Lopez CB, et al. IL-11 regulates autoimmune demyelination. J Immunol. 2009;183(7):4229–4240.
   PubMed Web of Science ®Google Scholar
• Favors SE, Curd LM, Gregg RK. Use of the anti-inflammatory cytokine interleukin-11 to reverse HIV-1gp120 repression of a natural killer cell line. Cell Immunol. 2012;276(1–2):1–5.
   Web of Science ®Google Scholar